Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities

May 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
54 patients in long term care facilities. 6% death with HCQ+AZ compared to 22% using a naive indirect comparison.
Ahmad et al., 18 May 2020, preprint, 5 authors.
This PaperHCQAll
Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities
MD, MPH, FCCP Imtiaz Ahmad, MD Mohammud Alam, MD, MPH Ryan Saadi, Saborny Mahmud, BS Emily Saadi
Importance: Patients in long-term care facilities (LTCF) are at a high-risk of contracting COVID-19 due to advanced age and multiple comorbidities. Without effective treatments, outbreaks in such facilities will become commonplace and will result in severe morbidity and mortality. The effectiveness of doxycycline (DOXY) and hydroxychloroquine (HCQ) combination therapy in high risk COVID-19 patients in longterm care facilities is not yet understood. Objective: The goal of this analysis is to describe outcomes after use of DOXY-HCQ combination in high-risk COVID-19 patients in LTCF. Design: Case-series analysis. Setting: Three (3) LTCFs in New York. Participants: From March 19 to March 30, 2020, fifty-four (54) patients, residents of three (3) LTCFs in New York and diagnosed (confirmed or presumed) with COVID-19, were included in this analysis. Exposure: All patients who were diagnosed (confirmed or presumed) with COVID-19 received DOXY-HCQ combination therapy along with standard of care. Main Outcomes and Measures: Patients characteristics, clinical recovery, radiological improvements, medication side-effects, hospital transfer, and death were assessed as outcome measures. Results: A series of fifty-four (54) high-risk patients, who developed a sudden onset of fever, cough, and shortness of breath (SOB) and were diagnosed or presumed to have COVID-19, were started with a combination of DOXY-HCQ and 85% (n=46) patients showed clinical recovery defined as: resolution of .
So far, no study was published from the United States using HCQ alone or in combination with AZ or DOXY. As a matter of fact, this study is the first case series conducted globally using a combination of DOXY-HCQ in COVID-19 patients in nursing home settings. We treated our moderate to severe patients in out-of-hospital settings and prevented hospital transfer in the majority of patients. Naive Indirect Comparison showed a better outcome than the data reported in MMWR (reported on March 26, 2020) 17 from a long-term care facility in King County, Washington where 57% of patients were hospitalized and 22% patients died. This effect can possibly be explained by the anti-inflammatory mechanism of action of DOXY-HCQ. However, data from the LTCF from King County, Washington was found to be similar to our population. These data also showed a reduction of hospitalization by 44% among LTCF residents compared to previously reported data by similar populations in MMWR. A limitation of our case-series analysis is that there was no control population available. Conclusion: DOXY and HCQ combination therapy is known to be anti-inflammatory, and immunomodulatory in both in-vitro and in-vivo studies. In addition, HCQ has anti-viral properties. Although this sample size is small (n=54), the results suggest that early intervention of DOXY-HCQ may improve the clinical outcome of high-risk COVID-19 patients suffering from moderate-severe symptoms in LTCF. These data is also associated with a..
Caprio, Lembo, Costanzo, Balato, Monfrecola, Anti-Inflammatory Properties of Low and High Doxycycline Doses: AnIn VitroStudy, Mediators of Inflammation, doi:10.1155/2015/329418
Castro, Vado-Solis, Perez-Osorio, Fredeking, Modulation of Cytokine and Cytokine Receptor/Antagonist by Treatment with Doxycycline and Tetracycline in Patients with Dengue Fever, Clinical and Developmental Immunology, doi:10.1155/2011/370872
Cazalis, Bodet, Gagnon, Grenier, Doxycycline reduces lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex vivo human whole blood models, J Periodontol, doi:10.1902/jop.2008.080051
Cerisano, Buonamici, Valenti, Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodeling: the TIPTOP trial, European Heart Journal, doi:10.1093/eurheartj/eht420
Chen Jun, Liu Danping, Liu Li, A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19), J Zhejiang Univ (Med Sci, doi:10.3785/j.issn.1008-9292.2020.03.03
Chen, Hu, Zhang, Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, medRxiv, doi:10.1101/2020.03.22.20040758
Cheung, Sawicki, Wozniak, Wang, Radomski et al., Matrix Metalloproteinase-2 Contributes to Ischemia-Reperfusion Injury in the Heart, Circulation, doi:10.1161/01.cir.101.15.1833
Conti, Ronconi, Caraffa, Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.105949
Kalish, Koujak, Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations, Clin Immunol, doi:10.1016/j.clim.2004.07.012
Kim, Park, Im, Minocycline promotes the generation of dendritic cells with regulatory properties, Oncotarget, doi:10.18632/oncotarget.10810
Mcmichael, Clark, Pogosjans, COVID-19 in a Long-Term Care Facility -King County, Washington, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm6912e1
Shi, Qin, Shen, Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China, JAMA Cardiol. Published online, doi:10.1001/jamacardio.2020.0950
Swarnakar, Mishra, Paul, Bhattacharya, Paul, An alternative therapy for idiopathic pulmonary fibrosis by doxycycline through matrix metalloproteinase inhibition, Lung India, doi:10.4103/0970-2113.83972
Villarreal, Griffin, Omens, Dillmann, Nguyen et al., Early Short-Term Treatment With Doxycycline Modulates Postinfarction Left Ventricular Remodeling, Circulation, doi:10.1161/01.cir.0000089090.05757.34
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop